Published in Br J Cancer on July 11, 2006
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell (2008) 3.56
Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol (2012) 2.94
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med (2009) 2.29
Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes (2011) 2.28
Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood (2009) 2.26
An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PLoS One (2010) 2.08
Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev (2013) 2.05
Macrophages and therapeutic resistance in cancer. Cancer Cell (2015) 1.95
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol (2013) 1.54
Tumour macrophages as potential targets of bisphosphonates. J Transl Med (2011) 1.53
The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med (2015) 1.44
A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J Immunol (2011) 1.41
Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology (2013) 1.40
MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res (2011) 1.40
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer (2012) 1.39
Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification. Stem Cells (2009) 1.33
Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia (2009) 1.33
ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res (2013) 1.32
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology (2013) 1.29
Role of CD11b+ macrophages in intraperitoneal lipopolysaccharide-induced aberrant lymphangiogenesis and lymphatic function in the diaphragm. Am J Pathol (2009) 1.28
S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res (2011) 1.25
The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron (2010) 1.23
Myeloid cells contribute to tumor lymphangiogenesis. PLoS One (2009) 1.22
Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc Natl Acad Sci U S A (2013) 1.16
Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol (2015) 1.15
Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci (2010) 1.14
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer (2010) 1.13
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res (2013) 1.11
Myeloid cell trafficking and tumor angiogenesis. Cancer Lett (2006) 1.10
Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res (2012) 1.06
Phenotypic and functional delineation of murine CX(3)CR1 monocyte-derived cells in ovarian cancer. Neoplasia (2009) 1.05
Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease. J Virol (2008) 1.01
Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer (2011) 1.00
Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem (2012) 1.00
Inadequate clearance of translocated bacterial products in HIV-infected humanized mice. PLoS Pathog (2010) 1.00
Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia (2014) 0.99
Strategies to increase drug penetration in solid tumors. Front Oncol (2013) 0.99
The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone (2009) 0.99
Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia (2015) 0.99
Macrophage and T cell produced IL-10 promotes viral chronicity. PLoS Pathog (2013) 0.98
Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol Pharm (2013) 0.97
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat Commun (2015) 0.97
The angiogenic response of the aorta to injury and inflammatory cytokines requires macrophages. J Immunol (2008) 0.96
Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo. Oncogene (2013) 0.96
Immune cells and angiogenesis. J Cell Mol Med (2009) 0.96
Innovative immunohistochemistry identifies MMP-9 expressing macrophages at the invasive front of murine HCC. World J Hepatol (2010) 0.95
Bone marrow stromal cell transplants prevent experimental enterocolitis and require host CD11b+ splenocytes. Gastroenterology (2010) 0.94
Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas. Front Immunol (2014) 0.94
Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice. BMC Immunol (2011) 0.94
Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm (2012) 0.94
T cells contribute to tumor progression by favoring pro-tumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma. PLoS One (2011) 0.93
Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBioMedicine (2014) 0.93
The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 0.92
The dual roles of homeobox genes in vascularization and wound healing. Cell Adh Migr (2012) 0.92
Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis. J Immunol Res (2014) 0.92
Colon Macrophages Polarized by Commensal Bacteria Cause Colitis and Cancer through the Bystander Effect. Transl Oncol (2013) 0.91
Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy (2013) 0.91
Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia (2008) 0.91
The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells. Exp Cell Res (2008) 0.91
C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res (2014) 0.90
Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm (2016) 0.89
Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomedicine (Lond) (2014) 0.89
The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunity. Nat Commun (2015) 0.88
Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res (2013) 0.88
Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases. Theranostics (2015) 0.87
The role of tumor-associated macrophages in tumor vascularization. Vasc Cell (2013) 0.87
Macrophages modulate cardiac function in lipotoxic cardiomyopathy. Am J Physiol Heart Circ Physiol (2012) 0.86
Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1. Viral Immunol (2009) 0.86
ATG16L1 deficiency in macrophages drives clearance of uropathogenic E. coli in an IL-1β-dependent manner. Mucosal Immunol (2015) 0.86
Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. Onco Targets Ther (2016) 0.86
Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget (2015) 0.86
Herpesvirus entry mediator regulates hypoxia-inducible factor-1α and erythropoiesis in mice. J Clin Invest (2011) 0.85
Depletion of resident macrophages does not alter sensory regeneration in the avian cochlea. PLoS One (2012) 0.85
Longitudinal study of tumor-associated macrophages during tumor expansion using MRI. NMR Biomed (2011) 0.85
VEGF and pleiotrophin modulate the immune profile of breast cancer. Cancers (Basel) (2010) 0.84
Tumor-associated macrophages and stromal TNF-α regulate collagen structure in a breast tumor model as visualized by second harmonic generation. J Biomed Opt (2013) 0.84
Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages. J Control Release (2016) 0.84
Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma. Cancers (Basel) (2011) 0.84
Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells. Vet Comp Oncol (2011) 0.82
Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biol Ther (2014) 0.82
Receptor-Mediated Mechanism Controlling Tissue Levels of Bioactive Lipid Oxidation Products. Circ Res (2015) 0.81
Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells. PLoS One (2014) 0.81
Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression. PLoS One (2010) 0.81
Bisphosphonates and cancer: what opportunities from nanotechnology? J Drug Deliv (2013) 0.81
Membrane versus soluble isoforms of TNF-α exert opposing effects on tumor growth and survival of tumor-associated myeloid cells. Cancer Res (2013) 0.80
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol (2011) 0.80
Depletion of cutaneous macrophages and dendritic cells promotes growth of basal cell carcinoma in mice. PLoS One (2014) 0.80
Peritoneal milky spots serve as a hypoxic niche and favor gastric cancer stem/progenitor cell peritoneal dissemination through hypoxia-inducible factor 1α. Stem Cells (2014) 0.79
Synthesis, characterization and in vitro evaluation of new composite bisphosphonate delivery systems. Int J Mol Sci (2014) 0.79
Reverse Microemulsion-Based Synthesis of (Bis)phosphonate-Metal Materials with Controllable Physical Properties: An Example Using Zoledronic Acid-Calcium Complexes. ACS Appl Mater Interfaces (2017) 0.79
Drug Trafficking into Macrophages via the Endocytotic Receptor CD163. Membranes (Basel) (2015) 0.78
Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil. Pharm Res (2008) 0.78
Macrophage Densities Correlated with CXC Chemokine Receptor 4 Expression and Related with Poor Survival in Anaplastic Thyroid Cancer. Endocrinol Metab (Seoul) (2016) 0.78
In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity (2002) 14.57
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods (1985) 6.11
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest (2004) 4.03
CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol (2004) 4.02
Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest (2005) 3.77
Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood (2004) 3.59
Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 3.57
STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol (2005) 3.32
Fundamental concepts of the angiogenic process. Curr Mol Med (2003) 3.16
Therapeutic targeting of the tumor microenvironment. Cancer Cell (2005) 2.86
Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol (2004) 2.26
CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med (2005) 2.23
Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res (2004) 2.12
Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer (2004) 2.12
Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem (1998) 1.83
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res (2005) 1.80
Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur J Immunol (1997) 1.73
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood (2004) 1.70
Lymphangiogenesis and tumor metastasis. Cell Tissue Res (2003) 1.50
Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J Virol (2000) 1.48
The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer (2005) 1.35
A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess (2004) 1.27
Immunological ignorance of solid tumors. Springer Semin Immunopathol (2005) 1.05
Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell Mol Life Sci (2004) 0.94
Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs. Biol Chem (1999) 0.93
Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res (2000) 0.89
Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer (2002) 0.87
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (1994) 11.22
Pelvic incidence: a fundamental pelvic parameter for three-dimensional regulation of spinal sagittal curves. Eur Spine J (1998) 6.81
Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell (1991) 6.49
ICOS is essential for effective T-helper-cell responses. Nature (2001) 4.01
Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature (2001) 3.99
Sagittal alignment of spine and pelvis regulated by pelvic incidence: standard values and prediction of lordosis. Eur Spine J (2005) 3.30
IgA production without mu or delta chain expression in developing B cells. Nat Immunol (2001) 3.26
Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells. Clin Exp Immunol (2005) 3.12
Variations in polyoma virus genotype in relation to tumor induction in mice. Characterization of wild type strains with widely differing tumor profiles. Am J Pathol (1987) 2.84
Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med (1997) 2.47
FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol (2000) 2.13
Constitutive activation of protein kinase B and phosphorylation of p47phox by a membrane-targeted phosphoinositide 3-kinase. Curr Biol (1996) 2.07
OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity (1999) 1.93
A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci (2006) 1.92
Deletion of self-reactive T cells before entry into the thymus medulla. Nature (1988) 1.88
A point mutation in CD28 distinguishes proliferative signals from survival signals. Nat Immunol (2001) 1.85
Induction of long-lived germinal centers associated with persisting antigen after viral infection. J Exp Med (1996) 1.80
Protective T cell-independent antiviral antibody responses are dependent on complement. J Exp Med (1999) 1.79
Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis. J Exp Med (1997) 1.77
Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur J Immunol (1997) 1.73
Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology. J Exp Med (1998) 1.70
Rapid neutrophil response controls fast-replicating intracellular bacteria but not slow-replicating Mycobacterium tuberculosis. J Infect Dis (2000) 1.68
Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med (1998) 1.65
Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation. Immunol Rev (1979) 1.64
The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci (2006) 1.63
On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11(-)/-) mutant mice. J Exp Med (1997) 1.59
Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med (1997) 1.55
Induction of diabetes is influenced by the infectious virus and local expression of MHC class I and tumor necrosis factor-alpha. J Immunol (1993) 1.55
Dendritic cells efficiently induce protective antiviral immunity. J Virol (1998) 1.53
Virion assembly defect of polyomavirus hr-t mutants: underphosphorylation of major capsid protein VP1 before viral DNA encapsidation. J Virol (1985) 1.50
Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J Virol (2000) 1.48
Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med (2000) 1.46
Free recirculation of memory B cells versus antigen-dependent differentiation to antibody-forming cells. J Immunol (1994) 1.45
Epidermolysis bullosa simplex with mottled pigmentation. J Am Acad Dermatol (1989) 1.44
Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity (1997) 1.39
New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia (2008) 1.37
Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice. Proc Natl Acad Sci U S A (1999) 1.35
Roles of macrophages in measles virus infection of genetically modified mice. J Virol (2001) 1.33
Comparative prevalence, incidence and short-term prognosis of cervical squamous intraepithelial lesions amongst HIV-positive and HIV-negative women. AIDS (1998) 1.32
Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci U S A (2000) 1.32
Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med (2000) 1.31
Homeostatic regulation of CD8+ T cells by perforin. Eur J Immunol (1999) 1.29
CD4(+) T cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability. J Exp Med (2000) 1.29
Detection of perforin and granzyme A mRNA in infiltrating cells during infection of mice with lymphocytic choriomeningitis virus. Eur J Immunol (1989) 1.24
Prenatal adverse effects of nicotine on the developing brain. Prog Brain Res (1988) 1.23
Immunosuppression by lymphocytic choriomeningitis virus infection: competent effector T and B cells but impaired antigen presentation. Eur J Immunol (1992) 1.23
Immunodeficiency of alymphoplasia mice (aly/aly) in vivo: structural defect of secondary lymphoid organs and functional B cell defect. Eur J Immunol (2000) 1.19
VEGF transiently disrupts gap junctional communication in endothelial cells. J Cell Sci (2001) 1.18
Interferon gamma-producing gammadelta T cell-dependent antibody isotype switching in the absence of germinal center formation during virus infection. Proc Natl Acad Sci U S A (1998) 1.17
Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity. J Exp Med (1996) 1.17
Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes. J Exp Med (1997) 1.15
Functional expression of the new gap junction gene connexin47 transcribed in mouse brain and spinal cord neurons. J Neurosci (2001) 1.13
Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc Natl Acad Sci U S A (1994) 1.12
Correlation of T cell independence of antibody responses with antigen dose reaching secondary lymphoid organs: implications for splenectomized patients and vaccine design. J Immunol (2000) 1.11
Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J Immunol (1999) 1.11
A simple method for evaluating the rejection of grafted spleen cells by flow cytometry and tracing adoptively transferred cells by light microscopy. J Immunol Methods (1997) 1.10
ER5, a tomato cDNA encoding an ethylene-responsive LEA-like protein: characterization and expression in response to drought, ABA and wounding. Plant Mol Biol (1997) 1.09
General and specific immunosuppression caused by antiviral T-cell responses. Immunol Rev (1999) 1.08
T and B cell tolerance and responses to viral antigens in transgenic mice: implications for the pathogenesis of autoimmune versus immunopathological disease. Immunol Rev (1991) 1.08
Expression of active protein kinase B in T cells perturbs both T and B cell homeostasis and promotes inflammation. J Immunol (2001) 1.05
Disruption of cytoskeletal structures results in the induction of the urokinase-type plasminogen activator gene expression. J Biol Chem (1990) 1.05
Antiviral B cell memory in the absence of mature follicular dendritic cell networks and classical germinal centers in TNFR1-/- mice. J Immunol (2000) 1.03
Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol (2001) 1.03
Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol Rev (1999) 1.02
Suppression of virus-specific antibody production by CD8+ class I-restricted antiviral cytotoxic T cells in vivo. J Virol (1992) 1.02
Protein kinase B/Akt is activated by polyomavirus middle-T antigen via a phosphatidylinositol 3-kinase-dependent mechanism. Oncogene (1998) 1.02
The preparation of large single bilayer liposomes by a fast and controlled dialysis. Biochim Biophys Acta (1978) 1.02
Lack of type VII collagen in unaffected skin of patients with severe recessive dystrophic epidermolysis bullosa. Dermatologica (1988) 1.01
Activation and nuclear translocation of mitogen-activated protein kinases by polyomavirus middle-T or serum depend on phosphatidylinositol 3-kinase. J Biol Chem (1995) 1.01
Immunoregulation of murine myeloma: isologous immunization with M315 induces idiotype-specific T cells that suppress IgA secretion by MOPC-315 cells in vivo. J Immunol (1979) 1.01
Apoptosis induced by ischemia and reperfusion in experimental lung transplantation. Ann Thorac Surg (2000) 1.01
Correlation of anti-viral B cell responses and splenic morphology with expression of B cell-specific molecules. Int Immunol (2000) 1.01
Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology (2004) 1.00
Association of p60c-src with polyoma virus middle-T antigen abrogating mitosis-specific activation. Nature (1991) 0.99
Induction of optimal anti-viral neutralizing B cell responses by dendritic cells requires transport and release of virus particles in secondary lymphoid organs. Eur J Immunol (2000) 0.99
Hypercholesterolemia exacerbates virus-induced immunopathologic liver disease via suppression of antiviral cytotoxic T cell responses. J Immunol (2001) 0.97
Perforin-independent regulation of dendritic cell homeostasis by CD8(+) T cells in vivo: implications for adaptive immunotherapy. Eur J Immunol (2001) 0.97
Polyomavirus middle-T antigen associates with the kinase domain of Src-related tyrosine kinases. J Virol (1996) 0.97
Phosphatase 2A associated with polyomavirus small-T or middle-T antigen is an okadaic acid-sensitive tyrosyl phosphatase. Eur J Biochem (1993) 0.97
Nitric oxide activation of p38 mitogen-activated protein kinase in 293T fibroblasts requires cGMP-dependent protein kinase. J Biol Chem (2000) 0.97
Functional analysis of type 1alpha cGMP-dependent protein kinase using green fluorescent fusion proteins. J Biol Chem (2001) 0.96
Antiviral protection and germinal center formation, but impaired B cell memory in the absence of CD19. J Exp Med (1998) 0.96
A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation. Oncogene (1997) 0.94
Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell Mol Life Sci (2004) 0.94
Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs. Biol Chem (1999) 0.93
Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. Biochem J (2001) 0.92
Ablation of Cx47 in transgenic mice leads to the loss of MUPP1, ZONAB and multiple connexins at oligodendrocyte-astrocyte gap junctions. Eur J Neurosci (2008) 0.91
DNA tumor viruses and Src family tyrosine kinases, an intimate relationship. Virology (1997) 0.91
[Pulmonary mucormycosis: difficulties in diagnosis and treatment]. Rev Mal Respir (2007) 0.90
The effects of charge and size on the interaction of unilamellar liposomes with macrophages. Biochim Biophys Acta (1984) 0.90
Mitosis-specific phosphorylation of polyomavirus middle-sized tumor antigen and its role during cell transformation. Proc Natl Acad Sci U S A (1993) 0.88
In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine (2000) 0.88
Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer (2002) 0.87
Phosphorylation of polyoma middle T antigen and cellular proteins in purified plasma membranes of polyoma virus-infected cells. EMBO J (1985) 0.87
TNF receptor 1-dependent beta cell toxicity as an effector pathway in autoimmune diabetes. J Immunol (1999) 0.87